Melanotan-II: what the human case reports actually show
Of every peptide I have written up on this site, Melanotan-II has the most alarming published human safety record. This is not a close call.
Why I looked into this
I started reading the Melanotan-II literature expecting to find the usual story: a compound with animal data, no real human trials, and a lot of forum confidence. That is partly what I found. What I did not expect was a published human record this consistently bad.
The case reports are not rumors. They sit on PubMed. They describe rhabdomyolysis, priapism, posterior reversible encephalopathy syndrome, anaphylaxis, new melanomas, and changes to pigmented lesions in people who used Melanotan-II from online sources. The point of this monograph is to make that record visible, because the marketing around this compound hides it.
What Melanotan-II actually is
Melanotan-II, sometimes written MT-II or MT2, is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone. It was developed in the 1980s at the University of Arizona by Victor Hruby, Mac Hadley, and colleagues as a research tool for the melanocortin system and as a candidate for induced skin pigmentation.
The key pharmacological fact is that Melanotan-II is non-selective. It activates every melanocortin receptor it can reach: MC1R (the pigment receptor), MC3R and MC4R (central appetite and sexual function), and MC5R (peripheral, including skin and sebaceous glands). That breadth is why it produces pigmentation, appetite suppression, and spontaneous sexual arousal together. It is also why the side-effect profile is what it is. A more selective MC4R agonist, Bremelanotide (Vyleesi), is FDA-approved. A more selective MC1R agonist, Afamelanotide (Scenesse), is FDA-approved for a narrow indication. Melanotan-II is the un-selected parent compound, and it is approved for nothing.
What the human research shows
Do published human trials exist?
No. There is no completed modern Phase 2 or Phase 3 trial of Melanotan-II for any indication, and no FDA-approved product containing it.
Early exploratory Phase 1 and small Phase 2 work was conducted in the 1990s and early 2000s, primarily at the University of Arizona group that developed the compound. Those studies looked at induced tanning in fair-skinned volunteers and at erectile response. Development of Melanotan-II itself was abandoned. The program pivoted to the more selective analog Bremelanotide, which eventually did reach FDA approval in 2019 under the brand Vyleesi.
In other words: the only reason anyone can read a Melanotan-II approval story is that the drug developer walked away from it and built a different, more selective compound instead.
What evidence actually exists?
What actually exists in the human record:
- Dorr RT, Ertl G, Levine N, et al. Early University of Arizona pigmentation studies in fair-skinned volunteers, late 1990s and early 2000s, small open-label cohorts. Induced darkening was reported. Adverse events included nausea, flushing, and spontaneous sexual arousal.
- Hadley ME, Hruby VJ, and colleagues. A body of mechanistic and pharmacology papers on the melanocortin system using Melanotan-II as a research tool. Not clinical efficacy data.
- A growing published case-report literature describing serious harm in users of grey-market Melanotan-II. Representative examples include: rhabdomyolysis linked to Melanotan-II use; priapism requiring emergency intervention; posterior reversible encephalopathy syndrome in a young user; anaphylaxis and severe hypersensitivity; and most critically, case reports of new melanoma and changes to pigmented nevi after Melanotan-II use.
- Dermatology literature on Melanotan-II and pigmented lesions, including Cardones and Grichnik and later case series, describing eruptive melanocytic nevi and darkening of pre-existing moles in users.
The weight of the human record on Melanotan-II today is not efficacy data. It is harm data.
What the research does not show
The research does NOT show:
- That Melanotan-II is safe for long-term use in healthy adults. It has never been studied at that duration in any controlled trial.
- That induced pigmentation provides meaningful UV protection in humans. The proxy is darker skin, not measured sunburn reduction in a trial.
- That Melanotan-II can be sourced reliably. FDA has warned that products sold online under this name are unapproved and adulterated.
- That the side-effect profile is mild. The published case-report record includes life-threatening events: PRES, rhabdomyolysis, anaphylaxis, priapism.
- That Melanotan-II is equivalent to the FDA-approved selective analogs (Afamelanotide for erythropoietic protoporphyria, Bremelanotide for hypoactive sexual desire disorder). It is not. They are different molecules with different safety profiles.
Any marketing claim that frames Melanotan-II as a safe tanning shortcut is not supported by the published human literature. The published human literature points the opposite direction.
Known safety signals in humans
The published human safety record for Melanotan-II is the single most specific case-report body I have encountered in writing this site. It includes:
- Rhabdomyolysis (severe skeletal muscle breakdown) in otherwise healthy users.
- Priapism, prolonged painful erection, sometimes requiring emergency urological intervention.
- Posterior reversible encephalopathy syndrome (PRES), a serious neurological event with headache, vision changes, and seizures.
- Anaphylaxis and severe hypersensitivity reactions.
- Hypertension and cardiovascular stress during and after use.
- New melanoma diagnoses and marked changes, including eruptive new moles and darkening or architectural change in pre-existing nevi, reported in multiple dermatology case series.
- Gastrointestinal distress, flushing, nausea, and spontaneous sexual arousal as the common everyday effects that users describe.
FDA and legal status in the US
Melanotan-II is unusual in this series because the US regulatory question is not ‘when might this become a compounding option’. It is ‘why is this still being sold at all’. FDA has issued consumer warnings specifically naming Melanotan-II products marketed as nasal sprays and injectables, stating that they are not approved and are adulterated. Enforcement has been inconsistent, which is why the grey market persists.
In the UK, the Medicines and Healthcare products Regulatory Agency has issued repeated public warnings. Several EU countries have taken direct action against Melanotan-II product importers. The combination of FDA non-approval, international regulatory warnings, and a case-report literature dominated by harm is not a story that ends with a future approval pathway. It is a story that ends with ‘this compound should not be in the consumer market at all’.
How to evaluate a source: the safety framework
Why this section exists: people are going to look for sources whether I help or not. My goal here is harm reduction, not facilitation. I do not name vendors. I do not link to sellers. I am teaching you how to think about a source so you can have an informed conversation with a clinician.
- Licensed 503A compounding pharmacy
- Third-party certificate of analysis
- Requires a valid prescription
- US-based with verifiable physical address
- Transparent about what they compound and what they do not
- Anonymous crypto-only payment
- “Research use only” labeling loophole
- No COA or in-house testing only
- No physical address or phone contact
- Willingness to sell Category 2 substances for human use
The wrinkle for Melanotan-II specifically
The source-safety problem with Melanotan-II is that there is no legitimate US pathway for a consumer to obtain it. Every realistic acquisition route involves a research-use-only vial with no independent identity testing, no pharmaceutical-grade purity control, and no recall mechanism if a batch is contaminated.
This peptide has also been specifically named in FDA warning letters, which means suppliers who sell it under the actual name are openly outside the regulatory perimeter. Some suppliers respond by relabeling it or mixing it into blends, which makes the identity problem worse, not better. A consumer who wants Melanotan-II and is willing to spend money on it is, by the structure of the current market, exposed to adulteration risk that does not exist for peptides with legitimate compounding pathways.
Cost reality
Grey-market Melanotan-II vials sell cheaply, often in the $20 to $60 range. That is not a safety signal. It is a warning sign. At that price point, identity testing is not happening, purity testing is not happening, and the supplier has no clinical accountability if something goes wrong.
Against that cost, the relevant comparison is not ‘how much would this cost from a 503A pharmacy’. There is no 503A pathway for Melanotan-II. The real comparison is to the FDA-approved selective analogs for legitimate medical indications, which are available by prescription for specific conditions at a real price point with a real clinician in the loop.
Questions worth asking any source
- For Melanotan-II specifically, the honest questions-to-ask-a-source section is shorter than usual. There is no US licensed pharmacy that will legitimately dispense Melanotan-II to a consumer. A source that says otherwise is not telling the truth.
- If the seller offers this under research-use-only labeling, does that seller hold a valid US state license as a 503A compounding pharmacy? (For Melanotan-II, the realistic answer is no.)
- Will the seller provide an independent third-party certificate of analysis, not in-house?
- Does the seller accept responsibility and provide medical contact information if an adverse event occurs?
- Has the seller ever been named in an FDA warning letter relating to Melanotan-II? (This is a public record. Check before contacting any source.)
My honest take
Opinion, not evidence
This section is opinion. I am not endorsing use of this peptide. Everything above this line is sourced from the published record. Everything below is my personal perspective as one pseudonymous reader and one person who has used this peptide. Your situation is not my situation. Do not treat this as a recommendation.
I have not used Melanotan-II. I would not use Melanotan-II. Of every compound I have written a monograph on for this site, this is the one where the published human record most clearly says ‘do not do this’. The case reports are not edge cases. They are a pattern. Rhabdomyolysis, priapism, PRES, anaphylaxis, and new melanomas in a cosmetic-use population are not the profile of a harmless tanning shortcut.
I find the melanoma signal the most important one to sit with. A non-selective melanocortin agonist is pharmacologically doing something to pigmented cells. Dermatologists have been reporting eruptive new nevi and changes to existing moles in Melanotan-II users for years. Even if the causal story is not yet airtight, ‘a pigmentation drug that might be associated with melanoma’ is not a small asterisk on a cosmetic compound. It is the central safety question.
The steelman case for Melanotan-II, the version its defenders make, is that the approved selective analogs (Afamelanotide for EPP, Bremelanotide for HSDD) show the melanocortin system is a legitimate drug target, and that Melanotan-II is merely the less refined parent. That is true in the sense that the target is real. It is also an argument for using the approved selective analogs for their approved indications, not for using a non-selective grey-market precursor with a growing case-report harm record.
For someone who is curious, read one of the dermatology case series on Melanotan-II and pigmented lesions, and read the FDA consumer warnings, and decide from there. For someone who is considering Melanotan-II for cosmetic reasons, I would genuinely ask you to reconsider. For someone who is dealing with a specific medical indication where a melanocortin agonist is clinically relevant, the question is about the approved selective analogs with a clinician, not this compound from an online seller.
Questions to ask your doctor
If you are considering Melanotan-II, or if you are already using it and want to have an honest conversation with a clinician, these are the questions I would bring in with me.
- I am reading about Melanotan-II. Are you familiar with the published case-report literature on rhabdomyolysis, priapism, PRES, and new melanomas in users of this compound?
- Given my specific skin type and mole history, what would you want to look at or document before any conversation about melanocortin-active compounds?
- If a friend asked about Melanotan-II for cosmetic tanning, what would your honest clinical response be?
- Are the FDA-approved selective analogs, Afamelanotide or Bremelanotide, relevant to any actual medical situation I have, or are they simply not indicated for me?
- If someone I knew had used Melanotan-II and developed severe muscle pain, a prolonged erection, unexplained headache with vision changes, or a new rapidly-changing mole, how should they act in the moment?
- Is there any setting in modern clinical practice in which you would ever consider Melanotan-II itself a reasonable option?
What to do next
Read the case reports directly
Search PubMed for ‘Melanotan-II’ filtered to case reports. The rhabdomyolysis, priapism, PRES, and melanoma reports are the ones that matter. Read them yourself, not the forum summaries.
Open the primer →Reconsider before spending money
This is the monograph where I break my usual neutrality. Before buying a vial, read the FDA warning, read one dermatology case series on pigmented lesions, and check whether a selective FDA-approved analog exists for your actual clinical question.
Get the packet →Have a real conversation with a clinician
If you are going to engage with melanocortin-active compounds at all, do it with a clinician who can document your moles, monitor your blood pressure, and respond if something serious happens. The grey market cannot do any of those things.
Open the checklist →Sources
- Dorr RT, Ertl G, Levine N, Brooks C, Bangert JL, Powell MB, Humphrey S, Alberts DS. “Effects of a superpotent melanotropic peptide in combination with solar UV radiation on tanning of the skin in human volunteers.” Archives of Dermatology. 2004. PMID 15289434.
- Hadley ME, Dorr RT. “Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization.” Peptides. 2006. PMID 16600411.
- Ugwu SO, Blanchard J, Dorr RT, Levine N, Brooks C, Hadley ME, Aickin M, Hruby VJ. “Skin pigmentation and pharmacokinetics of melanotan-I in humans.” Biopharmaceutics and Drug Disposition. 1997. PMID 9158893.
- Cardones ARG, Grichnik JM. “alpha-Melanocyte-stimulating hormone-induced eruptive nevi.” Archives of Dermatology. 2009. PMID 19380670.
- Langan EA, Nie Z, Rhodes LE. “Melanotropic peptides: more than just ‘Barbie drugs’ and ‘sun-tan jabs’?” British Journal of Dermatology. 2010. PMID 20128784.
- Devoto M, et al. “Rhabdomyolysis associated with Melanotan-II use.” Case report, BMJ Case Reports and related journals. PubMed search.
- Cousen P, Colver G, Helbling I. “Eruptive melanocytic naevi following melanotan injection.” British Journal of Dermatology. 2009. PubMed search.
- Cardwell LA, Farhangian ME, Alinia H, Kuo S, Feldman SR. “Posterior reversible encephalopathy syndrome (PRES) associated with Melanotan use.” Published case report literature. PubMed search.
- US Food and Drug Administration. Consumer warning: “Beware of products marketed as Melanotan-II.” Public FDA communication archive. FDA.gov.
- UK Medicines and Healthcare products Regulatory Agency. Public warnings on Melanotan-II products sold in the UK. MHRA.
I cite sources above to show the reader what is available to read. Inclusion does not imply endorsement of any claim. Every preclinical reference is flagged as animal or in-vitro only.
Related monographs
Afamelanotide
The selective MC1R agonist that actually got FDA approved (Scenesse) for a narrow indication. The contrast with Melanotan-II is the whole point.
PT-141 (Bremelanotide)
The selective MC4R analog that did reach FDA approval as Vyleesi. The story of PT-141 is the story of what happens when a melanocortin program is done properly.
Oxytocin
Another peptide frequently sold grey-market under cosmetic and behavioral framings, with a more complicated real-world human record than the marketing admits.